DOCSLIB.ORG

Synthesis and in Vitro Pharmacological Evaluation of a New Series of 5-HT1A 5-HT2A and 5-HT2C Receptor Ligands Containing a Norbornene Nucleus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ORIGINAL ARTICLES Dipartimento di Chimica Farmaceutica e Tossicologica1, Universita` degli Studi di Napoli “Federico II”, Napoli, Dipartimento di Farmacologia “G. Segre” 2, Universita` di Siena, Italy Synthesis and in vitro pharmacological evaluation of a new series of 5-HT1A 5-HT2A and 5-HT2C receptor ligands containing a norbornene nucleus F. Fiorino1, B. Severino1, F. De Angelis1, E. Perissutti1, E. Magli1, F. Frecentese1, A. Esposito1, P. Massarelli2, C. Nencini2, B. Viti2, V. Santagada1, G. Caliendo1 Received April 4, 2009, accepted May 7, 2009 Prof. Giuseppe Caliendo, Dipartimento di Chimica Farmaceutica e Tossicologica Universita` degli Studi di Napoli “Federico II”, Via D. Montesano, 49, 80131 Napoli, Italy [email protected] Pharmazie 64: 555–564 (2009) doi: 10.1691/ph.2009.9593 A series of 4-substituted piperazine derivatives bearing a norbornene nucleus have been prepared and their affinity for serotonin 5-HT1A, 5-HT2A and 5-HT2C receptors has been evaluated. Compounds showing the highest affinity have been selected and evaluated on dopaminergic (D1 and D2) and adrenergic (a1 and a2) receptors. The combination of structural elements (heterocyclic nucleus, oxyal- kyl chain and 4-substituted piperazine) known to be critical in order to have affinity on serotonin recep- tors and the proper selection of substituents led to compounds with higher receptor specificity and affinity. In binding studies, several molecules showed affinity in nanomolar range towards 5-HT1A,5- HT2A and 5-HT2C receptors and moderate to no affinity for other relevant receptors (D1,D2, a1 and a2). Compound 2q 4-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethoxy]-4-aza-tricyclo[5.2.1.02,6]dec-8-ene-3,5- dione (Ki ¼ 1.13 nM), was the most active and selective derivative for the 5-HT2C receptor with respect to other serotonin, dopaminergic and adrenergic receptors. Moreover, compound 3p showed mixed 5- HT2A/5-HT2C activity with affinity values in nanomolar range. 1. Introduction HT2C receptor is considered to be an attractive target for Evidence suggests that serotonin (5-hydroxytryptamine, 5- the design of novel drugs for treatment of CNS-related HT), is an important neurotransmitter in the central and diseases such as obesity, obsessive compulsive disorder, peripheral nervous systems (CNS and PNS, respectively), and sexual dysfunction, even if few 5-HT2C selective ago- implicated in numerous physiological and pathophysiolo- nists are known so far (Shimada et al. 2008). gical processes (Baumgarten et al. 1987; Martin et al. 5-HT1AR, 5-HT2AR and 5-HT2CR are G protein coupled 1998; Barnes et al. 1999; Hoyer et al. 2002; Shimada et al. receptors (GPCRs) (Sleight et al. 1991; Bikker et al. 1998) 2008). In fact, serotonin receptors (5-HTRs) may be in- that show an amino acid composition similar to adrenergic volved in impulsivity and alcoholism (De Vry et al. 1995; and dopaminergic receptors. In particular, the 5-HT1AR File et al. 1996), in the different phases of sleep (Neckel- transmembrane amino acid sequence presents 45% homol- mann et al. 1996), sexual behavior, appetite control, ther- ogy with the respective part of the a1-adrenergic receptor moregulation, cardiovascular function (Sleight et al. 1991; (Trump-Kallmeyer et al. 1992). Saxena et al. 1995) and recently has been found to show Several classes of agents are already known for their high growth-promoting activity and to be functionally related to affinity toward these receptors and, from a chemical point oncogenes (Dizeyi et al. 2004). In particular, the 5-HT1A of view, they can be subdivided into different classes receptor belongs to the superfamily of G-protein-coupled (aminotetralines, ergolines, arylpiperazines, indolylalkyl- receptors and negatively coupled to adenylyl cyclase amines, aporphines, arylalkylpiperidines, indoles and aryl- found in high concentration in the limbic system, where it oxyalkylamines). One of the most studied group is that of is thought to play a role in emotional processes and repre- long-chain arylpiperazine (LCAPs), (Lopez-Rodriguez sents a major target for research and drug development et al. 2002; Pessoa-Mahana et al. 2003) that have provided due to its implication in the pathophysiology and treat- interesting drugs acting on the CNS (buspirone, ziprasi- ment of major neuropsychiatric disorders, including de- done, aripiprazol) and compounds with a potential thera- pression, schizophrenia and anxiety. Moreover, the 5-HT2A peutical profile (adatanserin, mazapertine, flesinoxan, leco- receptor is known to play a key role in the action of psy- zotan, bifeprunox, tandospirone) which, among others, chedelics as well as being a therapeutic target for the treat- exert their action via 5-HT1A and 5-HT2A receptors. Their ment of schizophrenia (Parker et al. 2008), whereas the 5- diversified receptor binding profiles and intrinsic activities, Pharmazie 64 (2009) 9 555 ORIGINAL ARTICLES Scheme analyzed a new set of derivatives where the piperazine-N- alkyl moiety has been linked to a norbornene fragment O O (Scheme); introducing this heterocyclic nucleus in already reported compounds afforded arylpiperazine derivatives i N OH N O (CH2)n Cl with high affinity and selectivity towards 5-HT1A receptor (Fiorino et al. 2005). The relevance of the norbornene nu- O O (2a) n=2 (1) (3a) n=3 cleus as terminal fragment was already supported by un- ii constrained molecular dynamics simulations that showed a very stable orientation and position of the norbornene O part, emphasizing its favourable properties as anchoring group (Fiorino et al. 2005). In this paper, we describe a N O (CH2)n N N X new series of derivatives in which, this bicyclic nucleus O (2h-u) n=2 has been linked via two or three methylene spacing units (3h-u) n=3 to piperazines substituted in position 4 with aliphatic and/ or aromatic moieties, aiming to further explore the interac- Reagents and conditions: (i) Br(CH2)nCl, NaOH, absolute EtOH, 70 C, tion with 5-HT , 5-HT and 5-HT receptors. In parti- 24 h; (ii) 4-X-substituted-piperazine, K CO ,NaI,CHCN, reflux, 24 h 1A 2A 2C 2 3 3 cular, the choice of aliphatic substituents on the N-4 of depending on either the kind of substituent attached to the the piperazine moiety, that could appear in contrast with N-4 atom of the piperazine moiety or the nature of an the statement that protonable nitrogen and aromatic sys- amide or imide terminal fragment, open the possibility for tem are necessary for binding of aminergic ligand, was discovery of new potent therapeutic agents (Zajdel et al. done in order to obtain a complete structure-affinity and 2007). The influence of each part of the LCAP structures structure-selectivity relationship study. Instead, the role of oxygen atom in the chain linker was already clarified by on the 5-HT1A and 5-HT2A receptor affinity, intrinsic ac- tivity, and selectivity has been the subject of many SAR molecular modelling studies showing that the oxygen studies, whereas there are few evidences regarding the in- leads to more favourable changes in steric as well as elec- trostatic interaction between the norbornene derivatives teraction of the LCAP structures on the 5-HT2C receptor. In our laboratories, there has been an ongoing effort to and the receptor (Fiorino et al. 2005). Moreover, the multi- receptor profiles of promising derivatives were also evalu- develop new 5-HT1A agents (Caliendo et al. 1993, 1995, 1996, 1999, 2000, 2001, 2002; Fiorino et al. 2005, 2008) ated in terms of binding affinities for dopaminergic (D1, with high affinity and selectivity over other serotoninergic, D2) and adrenergic (a1, a2) receptors. dopaminergic and adrenergic receptors. In continuation of our research program, the aim of this work was also to 2. Investigations, results and discussion better clarify the structural features needed in order to make the LCAPs able for the interaction with 5-HT2A and The general strategy for the synthesis of the target com- 5-HT2C receptors. Based on this consideration we have pounds (Table 1) is summarized in Scheme 1. The general Table 1: Affinities of compounds 2h–u and 3h–u for 5-HT1A, 5-HT2A and 5-HT2C receptors O N O (CH2)n N N X O Compd. Receptor affinity Ki Æ SD (nM) X n 5-HT1A 5-HT2A 5-HT2C [3H]8OH-DPAT [3H]Ketanserin [3H]Mesulergine 2h 2 no affinity >104 >104 2i 2 no affinity >104 1590 Æ 524 OCH3 2l 2 no affinity >104 >104 OCH2CH3 2m 2 no affinity 25.3 Æ 2.6 6.79 Æ 0.08 OCH3 2n OCH2CH3 2 5.67 Æ 0.3 381 Æ 16 10.9 Æ 4.9 2o NC 2 4.82 Æ 0.05 83.7 Æ 1.9 6.61 Æ 0.26 556 Pharmazie 64 (2009) 9 ORIGINAL ARTICLES Table 1: Continued Compd. Receptor affinity Ki Æ SD (nM) X n 5-HT1A 5-HT2A 5-HT2C [3H]8OH-DPAT [3H]Ketanserin [3H]Mesulergine 2p H3C CH3 2 15.1 Æ 0.8 14.8 Æ 1.2 17.4 Æ 1.0 2q Cl 2 no affinity 153 Æ 70 1.13Æ 0.16 Cl 2r O 2 no affinity no affinity no affinity O 2s O 2 no affinity 3880 Æ 172 145 Æ 48 O 2t 2 no affinity >104 no affinity Cl 2u F 2 10.3 Æ 0.6 344 Æ 57 10.2 Æ 1.2 F 3h 3 no affinity >104 19.4 Æ 0.8 3i 3 no affinity no affinity no affinity OCH3 3l 3 no affinity >104 11.0 Æ 5.7 OCH2CH3 3m 3 no affinity 71.4 Æ 1.0 4.56 Æ 0.37 OCH3 4 3n OCH2CH3 3 >10 397 Æ 24 5.02 Æ 0.22 3o NC 3 >104 18.8 Æ 1.0 no affinity 3p H3C CH3 3 no affinity 7.48 Æ 0.18 5.16 Æ 0.12 3q Cl 3 >104 13.4 Æ 1.4 no affinity Cl Pharmazie 64 (2009) 9 557 ORIGINAL ARTICLES Table 1: Continued Compd.
Recommended publications
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities

    A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities

    77 A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities Hernán Pessoa-Mahana* 1 ; Ramiro Araya-Maturana1 , Claudio Saitz, B.1 and C. David Pessoa-Mahana2 1Departamento de Química Orgánica y Fisicoquímica. Facultad de Ciencias Químicas y Farmacéuticas. Universidad de Chile. Olivos 1007.Casilla 233. Santiago 1. Chile 2Departamento de Farmacia. Facultad de Química. Pontificia Universidad Católica de Chile. Vicuña Mackenna 4860-Casilla 306, Correo 22 Santiago-Chile Abstract: The present review discusses the synthetic strategies of new ligands exhibiting mainly 5-HT1A binding affinities. Specifically we focused our attention in the synthesis of compounds structurally related to arylpiperazine, 2-aminotetralin, and benzopyran derivatives. Keywords: serotonin, 5-HT1A ligands, arylpiperazines, aminotetralins, benzopyrans. INTRODUCTION During the last 15 years, seven distinct families of 5-HT receptors have been identified (5-HT1–5-HT7), and at least Depression is one of the most common illnesses, 15 subpopulations have been described for several of these affecting up to one-third of all people at the same time. [4,5]. The 5-HT1A receptors represent a major target for Depressive disorders encompass a variety of conditions neurobiological research and drug developments. A study on including two major forms of unipolar depression (i.e. major distribution of 5-HT1A receptors in the brains of various depression and dysthymia), adjustment disorders, animal species indicates that the highest densities are located subsyndromal depression (minor depression), seasonal in the hippocampus, septum, amygdale, and cortical limbic affective disorder (SAD), premenstrual dysphoric disorder areas. The 5-HT1A receptors located in the raphe nuclei are (PMDD), postpartum depression, atypical depression and known as somatodendritic autoreceptors.
  • 1 Molecular Biology and Genomic Organization of G Protein–Coupled Serotonin Receptors Wesley K

    1 Molecular Biology and Genomic Organization of G Protein–Coupled Serotonin Receptors Wesley K

    THE SEROTONIN RECEPTORS T HE R ECEPTORS KIM A. NEVE, SERIES EDITOR The Serotonin Receptors: From Molecular Pharmacology to Human Therapeutics, EDITED BY Bryan L. Roth, 2006 The Adrenergic Receptors: In the 21st Century, EDITED BY Dianne M. Perez, 2005 The Melanocortin Receptors, EDITED BY Roger D. Cone, 2000 The GABA Receptors, Second Edition, EDITED BY S. J. Enna and Norman G. Bowery, 1997 The Ionotropic Glutamate Receptors, EDITED BY Daniel T. Monaghan and Robert Wenthold, 1997 The Dopamine Receptors, EDITED BY Kim A. Neve and Rachael L. Neve, 1997 The Metabotropic Glutamate Receptors, EDITED BY P. Jeffrey Conn and Jitendra Patel, 1994 The Tachykinin Receptors, EDITED BY Stephen H. Buck, 1994 The Beta-Adrenergic Receptors, EDITED BY John P. Perkins, 1991 Adenosine and Adenosine Receptors, EDITED BY Michael Williams, 1990 The Muscarinic Receptors, EDITED BY Joan Heller Brown, 1989 The Serotonin Receptors, EDITED BY Elaine Sanders-Bush, 1988 The Alpha-2 Adrenergic Receptors, EDITED BY Lee Limbird, 1988 The Opiate Receptors, EDITED BY Gavril W. Pasternak, 1988 The Alpha-1 Adrenergic Receptors, EDITED BY Robert R. Ruffolo, Jr., 1987 The GABA Receptors, EDITED BY S. J. Enna, 1983 The Serotonin Receptors From Molecular Pharmacology to Human Therapeutics Edited by Bryan L. Roth, MD, PhD Department of Biochemistry Case Western Reserve University–School of Medicine Cleveland, OH © 2006 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512 www.humanapress.com For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341, E-mail: [email protected]; or visit our Website: http://www.
  • Antidepressant Potential of Nitrogen-Containing Heterocyclic Moieties: an Updated Review

    Antidepressant Potential of Nitrogen-Containing Heterocyclic Moieties: an Updated Review

    Review Article Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review Nadeem Siddiqui, Andalip, Sandhya Bawa, Ruhi Ali, Obaid Afzal, M. Jawaid Akhtar, Bishmillah Azad, Rajiv Kumar Department of ABSTRACT Pharmaceutical Chemistry, Depression is currently the fourth leading cause of disease or disability worldwide. Antidepressant is Faculty of Pharmacy, Jamia Hamdard approved for the treatment of major depression (including paediatric depression), obsessive-compulsive University, Hamdard disorder (in both adult and paediatric populations), bulimia nervosa, panic disorder and premenstrual Nagar, New Delhi - dysphoric disorder. Antidepressant is a psychiatric medication used to alleviate mood disorders, such as 110 062, India major depression and dysthymia and anxiety disorders such as social anxiety disorder. Many drugs produce an antidepressant effect, but restrictions on their use have caused controversy and off-label prescription a Address for correspondence: risk, despite claims of superior efficacy. Our current understanding of its pathogenesis is limited and existing Dr. Sandhya Bawa, E-mail: sandhyabawa761@ treatments are inadequate, providing relief to only a subset of people suffering from depression. Reviews of yahoo.com literature suggest that heterocyclic moieties and their derivatives has proven success in treating depression. Received : 08-02-11 Review completed : 15-02-11 Accepted : 17-02-11 KEY WORDS: Antidepressant, depression, heterocyclic epression is a chronic, recurring and potentially life- monoamine oxidase inhibitors (MAOIs, e.g. Nardil®) tricyclic D threatening illness that affects up to 20% of the population antidepressants (TCAs, e.g. Elavil). They increases the synaptic across the globe.[1] The etiology of the disease is suboptimal concentration of either two (5-HT and NE) or all three (5-HT, concentrations of the monoamine neurotransmitters serotonin NE and dopamine (DA)) neurotransmitters.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Pjp4'2003.Vp:Corelventura

    Pjp4'2003.Vp:Corelventura

    Copyright © 2003 by Institute of Pharmacology Polish Journal of Pharmacology Polish Academy of Sciences Pol. J. Pharmacol., 2003, 55, 543–552 ISSN 1230-6002 NOVEL 4-ALKYL-1-ARYLPIPERAZINES AND 1,2,3,4-TETRAHYDROISOQUINOLINES CONTAINING DIPHENYLMETHYLAMINO OR DIPHENYLMETHOXY FRAGMENT WITH DIFFERENTIATED 5-HT1A/5-HT2A/D2 RECEPTOR ACTIVITY Maria H. Paluchowska1,#, Maria J. Mokrosz 1, Sijka Charakchieva-Minol1, Beata Duszyñska1, Aneta Kozio³1, Anna Weso³owska2, Katarzyna Stachowicz2, Ewa Chojnacka-Wójcik2 Department of Medicinal Chemistry, Department of New Drugs Research, Institute of Pharmacology, Polish Academy of Sciences, Smêtna 12, PL 31-343 Kraków, Poland Novel 4-alkyl-1-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with dif- ferentiated 5-HT)/5-HT )/D receptor activity. M.H. PALUCHOWSKA, M.J. MOKROSZ , S. CHARAKCHIEVA-MINOL, B. DUSZYÑSKA, A. KOZIO£, A. WESO£OWSKA, K. STACHOWICZ, E. CHOJNACKA- WÓJCIK. Pol. J. Pharmacol., 2003, 55, 543–552. Two series of 4-alkyl-1-arylpiperazines (1–4) and 1,2,3,4-tetrahydroiso- quinolines (5, 6) with diphenylmethylamino (series a) or diphenylmethoxy (series b) fragment were synthesized in order to obtain potential ligands of 5-HT) and/or 5-HT ) and dopamine D receptors. Four new arylpiperazi- nes (1a, 3a, 1b, 3b) were found to demonstrate high 5-HT) receptor affinity (KE = 1.5–35 nM); among them, 3a exhibited satisfactory 5-HT ) receptor affinity (KE = 74 nM). Only compounds 1b and 2b showed moderate affinity for D receptor sites (KE = 123 and 128 nM, respectively). Compounds 1a, 3a, 1b and 3b were investigated in vivo to determine their functional activity at 5-HT) receptors; additionally, 3a was tested for 5-HT ) receptor activity.
  • Providing for Duty-Free Treatment for Specified Pharmaceutical Active

    Providing for Duty-Free Treatment for Specified Pharmaceutical Active

    13 . 3 . 97 I EN I Official Journal of the European Communities No L 71 / 1 I (Acts whose publication is obligatory) COUNCIL REGULATION (EC) No 467/97 of 3 March 1997 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an 'international non-proprietary name' (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals and withdrawing duty-free treatment as pharmaceutical products from certain INNs whose predominant use is not pharmaceutical THE COUNCIL OF THE EUROPEAN UNION , whereas in the context of the review it was concluded that it was appropriate to rectify the situation with regard Having regard to the Treaty establishing the European to certain INNs whose use was predominantly non­ Community, and in particular Article 113 thereof, pharmaceutical and which had been inadvertently included among those INNs already receiving duty-free treatment, Having regard to the proposal from the Commission , Whereas, in the course of the Uruguay Round negotia­ HAS ADOPTED THIS REGULATION : tions the Community and a number of countries discussed duty-free treatment of pharmaceutical products ; Article 1 Whereas the participants in those discussions concluded that in addition to products falling within the Harm­ From 1 April 1997 the Community shall also accord onized System (HS) Chapter 30 and HS headings 2936 , duty-free treatment for the INNs listed in Annex I as well 2937, 2939 and 2941 , duty-free treatment should be given as the salts, esters and hydrates of such products . to designated pharmaceutical active ingredients bearing an 'international non-proprietary name' (INN) from the Article 2 World Health Organization as well as specified salts , esters and hydrates of such INNs, and also to designated From 1 April 1997 the Community shall also grant duty­ products used for the production and manufacture of free treatment for the products used in the production finished products ; and manufacture of pharmaceutical products listed in Annex II .
  • (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley Et Al

    (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley Et Al

    USOO6197764B1 (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley et al. (45) Date of Patent: *Mar. 6, 2001 (54) CLOZAPINE COMPOSITIONS AND USES FOREIGN PATENT DOCUMENTS THEREOF 0599 576A1 1/1994 (EP). (75) Inventors: Matthews O. Bradley, Laytonsville, 693498 1/1996 (EP). MD (US); Victor E. Shashoua, 61204136 11/1984 (JP). Belmont, MA (US); Charles S. 06-072868 3/1994 (JP). Swindell, Merion; Nigel L. Webb, 6072868 3/1994 (JP). Bryn Mawr, both of PA (US) 7082146 3/1996 (JP). 8151334 6/1996 (JP). (73) Assignee: Protarga, Inc., Conshohocken, PA (US) 9030963 2/1997 (JP). (*) Notice: Subject to any disclaimer, the term of this WO 89/07938 9/1989 (WO). patent is extended or adjusted under 35 WO 96/04001 2/1996 (WO). U.S.C. 154(b) by 0 days. WO 96/22303 7/1996 (WO). WO 96/27380 9/1996 (WO). This patent is Subject to a terminal dis WO98/17325 4/1998 (WO). claimer. OTHER PUBLICATIONS (21) Appl. No.: 08/978,541 (22) Filed: Nov. 26, 1997 Bourat, et al., "Long Chain Esters of Pipotiazine as Lon g-Acting Psychotropic Pro-Drug, Med. Chem. Proc. Int. (51) Int. Cl. .............................................. A61K 31/00 Symp. 5th (1976) pp. 105-114. (52) U.S. Cl. ........................... 514/218; 514/219; 514/220 Lohr, et al., “Neuroleptic-Induced Movement Disorders . (58) Field of Search ..................................... 514/218, 219, ..", Psychiatry, vol. 3, (1989). 514/220 Makino, et al., Chemical Abstracts, vol. 106, No. 12, (56) References Cited (90.177x) issued Mar. 23, 1987, “Pharmaceuticals Permeable to Blood-Brain Barrier'.
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr

    (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr

    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev

    PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev

    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
  • Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients

    Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients

    This is a repository copy of Antipsychotics for treatment of delirium in hospitalised non-ICU patients. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132847/ Version: Published Version Article: Burry, Lisa, Mehta, S.R., Perreault, M.M et al. (6 more authors) (2018) Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews. CD005594. ISSN 1469-493X https://doi.org/10.1002/14651858.CD005594.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Antipsychotics for treatment of delirium in hospitalised non- ICU patients (Review) Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews 2018, Issue 6.